Isoniazid monoresistant tuberculosis treatment outcomes in Puducherry, South India - A mixed methods study
- PMID: 39067963
- DOI: 10.1016/j.ijtb.2024.05.013
Isoniazid monoresistant tuberculosis treatment outcomes in Puducherry, South India - A mixed methods study
Abstract
Setting: On a programmatic basis, a new regimen was introduced in the National Tuberculosis Elimination Programme for isoniazid monoresistant tuberculosis in a few states in India.
Objective: To describe the clinical attributes and treatment outcomes of isoniazid mono-resistant tuberculosis patients on the new 6-month levofloxacin-containing regimen in Puducherry, India.
Design: The study is designed as a convergent parallel mixed-methods study: a retrospective cohort study and a descriptive qualitative study. A total of 180 Hr-TB patient health records were reviewed, and in-depth interviews with 35 participants were conducted. (20 Hr-TB patients and 15 HCWs).
Results: Of the total 180 Hr-TB patients included, we documented unfavourable outcomes in 26.1% of cases, and the KatG gene mutation was the most common mutation observed (63.9%). A significant risk of unfavourable outcomes was associated with low adherence and positive sputum at the third-month culture report. In interviewing the stakeholders, major challenges observed were the increased pill burden, delay in diagnosis, shortage of drugs, and lack of staff.
Conclusion: Hr-TB patients have difficulty in adhering to the 6-month levofloxacin regimen, with the need for rigorous early 3-month follow-up and assessment.
Keywords: 6 (H)RZE; Adherence; Lfx; Medication shortage; Turn-around time.
Copyright © 2024. Published by Elsevier B.V.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
